[Home]
[Full version]
Migration alert -- How tumor cells home in on the lymphatic system
Jun 11 ,Medicine & Health
A Swiss-based research team has published a new mechanistic description of how tumor cells migrate to the lymphatic system in the early stages of tumor metastasis. This new understanding holds significant potential for developing anti-metastasis therapies.
Scientists know that tumor cells spread via the lymphatic system, but they don’t understand the details of how this deadly migration takes place. In the June 2007 issue of the journal Cancer Cell, EPFL Professor Melody Swartz and postdoctoral researcher Jacqueline Shields provide an explanation along with data to support it.
Tumors produce excess fluid that continually percolates from the tumor towards nearby lymphatic vessels. The EPFL research shows how tumor cells use a clever chemical strategy to exploit this slow, one-way flow in order to migrate to functional lymphatic vessels.
As part of their intercellular drainage job, lymphatic tissues secrete small quantities of a signaling molecule. Cells migrate towards high concentrations of this molecule, so if they are close enough to the lymphatic to sense the molecule, they will migrate towards the vessel. Swartz’s group showed that tumor cells secrete this same molecule. Since lymphatics drain fluid, there will always be slow fluid flow going away from the tumor into the lymphatic vessel. This slow flow biases the concentration distribution of this molecule towards the lymphatic, and the tumor cell follows it, like the proverbial carrot on a stick. Near the vessel, concentrations of the signaling molecule are reinforced by the lymphatic’s own secretions, fine tuning the tumor cells’ migration and guaranteeing that they will home in on the lymphatic.
To demonstrate this new concept, the researchers engineered a tissue culture model of the tumor-lymphatic microenvironment and developed computational models to calculate the gradients of the signaling molecule.
The study provides the first evidence that tumor cells can both produce and use the same signaling molecule, and it highlights the significance of the biophysical environment in the vicinity of a tumor, particularly the existence of continuous slow flow in the direction of functional lymphatics.
This research could open new avenues for combating metastasis, says Swartz. “It implies that if a lymphatic was blocked, tumor cells would be less attracted to it. This means that tumor cells “know” which lymphatic vessels will be more effective routes for dissemination,” she explains. “Therapeutically, it indicates that a drug target for lymph node metastases could be blocking the signaling molecule or its receptor on the tumor cell.”
Source: Ecole Polytechnique Fédérale de Lausanne
Related stories:
Survival rates appear lower for scalp and neck melanoma than for other sites
Individuals with melanoma on their scalp or neck appear less likely to survive for five or 10 years than those with melanoma at other sites, according to a report in the April issue of Archives of Dermatology, one of the JAMA/Archives journals.
Hormone may be new drug target for preventing lymphedema, tumor spread
A hormone secreted by cells throughout the body and known to play a role in cardiovascular disease and other cell functions is also critical for proper formation of the lymphatic system in mice, according to research from the University of North Carolina at Chapel Hill School of Medicine.
Researchers train the immune system to deliver virus that destroys cancer in lab models
An international team of researchers led by Mayo Clinic have designed a technique that uses the body’s own cells and a virus to destroy cancer cells that spread from primary tumors to other parts of the body through the lymphatic system. In addition, their study shows that this technology could be the basis for a new cancer vaccine to prevent cancer recurrence. The study appeared in the Dec. 9 online issue of
Nature Medicine.
Lymphatic vessel and lymph node function are restored with growth factor treatment
The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.
Quantitative PET imaging finds early determination of effectiveness of cancer treatment
With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient’s response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors. Researchers have found that measuring a quantitative index—one that reflects the reduction of metabolic activity after chemotherapy first begins—adds accurate information about patients’ responses to first-line chemotherapy, according to a study in the October issue of the
Journal of Nuclear Medicine.
Venous origin of the mammalian lymphatic vasculature
In the October 1 issue of G&D, Dr. Guillermo Oliver (St. Jude Children’s Research Hospital) and colleagues present new evidence to resolve a century-old debate over the origin of the mammalian lymphatic vasculature. Understanding the development of the lymphatic vasculature is integral to understanding its function in both health (mediating immunity and maintaining tissue fluid levels) and disease (lymphedema and spreading tumor metastasis).
Chromosomes tell tale of patient's risk for new, future cancer
Hodgkin's disease survivors who have greater genetic instability in their white blood cells are two-and-a-half times more likely to develop another type of cancer, researchers from The University of Texas M. D. Anderson Cancer Center report at the American Association for Cancer Research annual meeting in Los Angeles April 14-18.
Probe to detect spread of breast cancer co-developed by UH scientist
High-temperature superconductors hold the key to a handheld tool for surgeons that promises to be more accurate, cost-effective and safer than existing methods for staging and treating various cancers, including breast cancer.
[Home]
[Full version]